Great West Life Assurance Co. Can Boosts Position in Bio-Rad Laboratories, Inc. (BIO)

Great West Life Assurance Co. Can increased its stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 0.5% during the second quarter, according to its most recent filing with the SEC. The institutional investor owned 12,447 shares of the medical research company’s stock after buying an additional 67 shares during the period. Great West Life Assurance Co. Can’s holdings in Bio-Rad Laboratories were worth $2,816,000 as of its most recent filing with the SEC.

A number of other large investors also recently bought and sold shares of BIO. BlackRock Inc. boosted its stake in Bio-Rad Laboratories by 9,953.4% in the first quarter. BlackRock Inc. now owns 1,733,111 shares of the medical research company’s stock valued at $345,478,000 after buying an additional 1,715,872 shares in the last quarter. BlueCrest Capital Management Ltd boosted its stake in Bio-Rad Laboratories by 183.5% in the first quarter. BlueCrest Capital Management Ltd now owns 187,872 shares of the medical research company’s stock valued at $37,450,000 after buying an additional 121,602 shares in the last quarter. TimesSquare Capital Management LLC boosted its stake in Bio-Rad Laboratories by 17.2% in the first quarter. TimesSquare Capital Management LLC now owns 611,700 shares of the medical research company’s stock valued at $121,936,000 after buying an additional 89,800 shares in the last quarter. Point72 Asset Management L.P. boosted its stake in Bio-Rad Laboratories by 640.9% in the first quarter. Point72 Asset Management L.P. now owns 94,100 shares of the medical research company’s stock valued at $18,758,000 after buying an additional 81,400 shares in the last quarter. Finally, Assenagon Asset Management S.A. bought a new stake in Bio-Rad Laboratories during the second quarter valued at approximately $14,956,000. 63.66% of the stock is currently owned by institutional investors and hedge funds.

Shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) opened at 212.43 on Monday. Bio-Rad Laboratories, Inc. has a 52-week low of $147.68 and a 52-week high of $242.79. The company has a market capitalization of $6.30 billion, a PE ratio of 419.82 and a beta of 0.91. The company has a 50-day moving average of $228.17 and a 200 day moving average of $213.43.

TRADEMARK VIOLATION NOTICE: This piece was reported by [[site]] and is the property of of [[site]]. If you are reading this piece on another site, it was illegally copied and republished in violation of United States & international trademark and copyright legislation. The original version of this piece can be viewed at [[permalink]].

Several equities research analysts recently commented on BIO shares. Zacks Investment Research raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and set a $244.00 price objective on the stock in a research report on Monday, May 1st. Deutsche Bank AG raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating and cut their price objective for the company from $220.00 to $195.00 in a research report on Wednesday, June 28th. BidaskClub raised shares of Bio-Rad Laboratories from a “hold” rating to a “buy” rating in a research report on Thursday, June 22nd. Jefferies Group LLC reaffirmed a “buy” rating and issued a $250.00 price objective on shares of Bio-Rad Laboratories in a research report on Thursday, April 27th. Finally, Wells Fargo & Company started coverage on shares of Bio-Rad Laboratories in a research report on Thursday, July 13th. They issued an “outperform” rating and a $250.00 price objective on the stock. One research analyst has rated the stock with a sell rating and five have issued a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $228.80.

In other Bio-Rad Laboratories news, EVP Michael Crowley sold 700 shares of the firm’s stock in a transaction on Friday, August 11th. The shares were sold at an average price of $215.91, for a total value of $151,137.00. Following the transaction, the executive vice president now directly owns 2,060 shares of the company’s stock, valued at $444,774.60. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. 28.29% of the stock is currently owned by company insiders.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc (Bio-Rad) is a manufacturer and distributor of its life science research and clinical diagnostics products. The Company operates through two segments: Life Science and Clinical Diagnostics. It manufactures and supplies the life science research, healthcare, analytical chemistry and other markets with a range of products and systems used to separate complex chemical and biological materials and to identify, analyze and purify their components.

Want to see what other hedge funds are holding BIO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bio-Rad Laboratories, Inc. (NYSE:BIO).